November 25 2009

NOSTRA-TRIAL - vasopharm is recruiting first patient in a phase IIa trial

The phase IIa is an explorative European multicentre placebo-controlled, randomized, double blind study examining safety and tolerability as well as pharmacodynamic and pharmacokinetic effects of the compound VAS203

vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announced the recruitment of the first patient in its clinical phase IIa NOSTRA trial (NO-Synthase inhibition in TRAumatic brain injury).

The phase IIa is an explorative European multicentre placebo-controlled, randomized, double blind study examining safety and tolerability as well as pharmacodynamic and pharmacokinetic effects of the compound VAS203. VAS203 is novel type NO-synthase inhibitor competing with the co-factor tetrahydrobiopterin. 

In total, 32 patients will be enrolled in five study centres. All study centres are routinely using the microdialysis technique which shall be instrumental to measure the NO- and energy metabolism as well as the presence of the compound in the brain tissue. The study is expected to run until the first quarter of 2011. 

About vasopharm:

vasopharm is focused on the development of therapeutics which permits modulating the bioavailability of biological NO, by addressing the entire NO/cGMP signal cascade and its functional counterpart NOX. vasopharm’s drug candidate VAS203 represents a completely new class of NOS modulators targeting cerebral vessels and cerebral tissue, thus preventing life threatening rises in intracranial pressure.

back